74 research outputs found
<Abstract of published report>Purification and partial characterization of an indomethacin hydrolyzing enzyme from pig liver.
<Abstract of Published Report>Purification and Characterization of Pranlukast Hydrolase from Rat Liver Microsomes : The Hydrolase is Identical to Carboxylesterase pI 6.2.
Suppression of HBV replication by the expression of nickase-and nuclease dead-Cas9
Kurihara, T., Fukuhara, T., Ono, C. et al. Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9. Sci Rep 7, 6122 (2017). https://doi.org/10.1038/s41598-017-05905-
<Abstract of Published Report>Hydrolytic Profile for Ester- or Amide-linkage by Carboxylesterases pI 5.3 and 4.5 from Human Liver.
Plasma Cytokine Profiles in Subjects with High-Functioning Autism Spectrum Disorders
Accumulating evidence suggests that dysregulation of the immune system is involved in the pathophysiology of autism spectrum disorders (ASD). The aim of the study was to explore immunological markers in peripheral plasma samples from non-medicated subjects with high-functioning ASD.A multiplex assay for cytokines and chemokines was applied to plasma samples from male subjects with high-functioning ASD (n = 28) and matched controls (n = 28). Among a total of 48 analytes examined, the plasma concentrations of IL-1β, IL-1RA, IL-5, IL-8, IL-12(p70), IL-13, IL-17 and GRO-α were significantly higher in subjects with ASD compared with the corresponding values of matched controls after correction for multiple comparisons.The results suggest that abnormal immune responses as assessed by multiplex analysis of cytokines may serve as one of the biological trait markers for ASD
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
PURPOSE: This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. MATERIALS AND METHODS: Eligible patients had platinum-resistant epithelial ovarian cancer, received ≤ 1 regimen after diagnosis of resistance, and had an Eastern Cooperative Oncology Group performance score of ≤ 1. Patients were randomly assigned 1:1 to nivolumab (240 mg once every 2 weeks [as one cycle]) or chemotherapy (GEM 1000 mg/m2 for 30 minutes [once on days 1, 8, and 15] followed by a week's rest [as one cycle], or PLD 50 mg/m2 once every 4 weeks [as one cycle]). The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), overall response rate, duration of response, and safety. RESULTS: Patients (n = 316) were randomly assigned to nivolumab (n = 157) or GEM or PLD (n = 159) between October 2015 and December 2017. Median OS was 10.1 (95% CI, 8.3 to 14.1) and 12.1 (95% CI, 9.3 to 15.3) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.0; 95% CI, 0.8 to 1.3; P = .808). Median PFS was 2.0 (95% CI, 1.9 to 2.2) and 3.8 (95% CI, 3.6 to 4.2) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.5; 95% CI, 1.2 to 1.9; P = .002). There was no statistical difference in overall response rate between groups (7.6% v 13.2%; odds ratio, 0.6; 95% CI, 0.2 to 1.3; P = .191). Median duration of response was numerically longer with nivolumab than GEM or PLD (18.7 v 7.4 months). Fewer treatment-related adverse events were observed with nivolumab versus GEM or PLD (61.5% v 98.1%), with no additional or new safety risks. CONCLUSION: Although well-tolerated, nivolumab did not improve OS and showed worse PFS compared with GEM or PLD in patients with platinum-resistant ovarian cancer
Establishment and characterization of a cell line (HCH-1) originating from a human clear cell carcinoma of the ovary
Kawaii meiru and Maroyaka neko: Mobile emoji for relationship maintenance and aesthetic expressions among Japanese teens
Drawing from the results of focus group interviews conducted between 2006 and 2010 in Japan, this paper examines the functions of emoji. Now that emoji have gained global recognition as seen in mobile applications, examining the way Japanese teens use emoji offers some insight into the way emoji use is practiced among teens in the global cultural context. The results highlight two functions of emoji in the context of mobile interactions: emoji allow Japanese teens to manage communication climate as well as to construct and express their aesthetic selves. Further research is needed to investigate to what extent these interaction norms, symbolic meanings, and electronic emotions are applicable to various cultural contexts in the era of smart phones. Such efforts will promote our further understanding of both current and future trends of teens’ mobile emoji use, emotional experiences, sense of the self, and relational concerns
- …